Related Experiment Video
Updated: May 9, 2025

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
Rheumatoid Arthritis That Developed in a Patient with Ulcerative Colitis During Adalimumab Therapy: A Case Report and
Takeshi Zoshima1,2, Makoto Horita1,2, Hiroyuki Kawahara1,2
1Department of Internal Medicine, Asanogawa General Hospital, Japan.
Rheumatoid arthritis (RA) is a rare complication of ulcerative colitis (UC). This case study highlights a patient who developed RA during tumor necrosis factor (TNF) inhibitor therapy for UC, suggesting RA can occur despite such treatments.
Area of Science:
- Gastroenterology
- Rheumatology
- Immunology
Background:
- Ulcerative colitis (UC) patients on tumor necrosis factor (TNF) inhibitors may experience joint issues.
- Rheumatoid arthritis (RA) is an uncommon manifestation in UC patients, particularly during anti-TNF therapy.
Purpose of the Study:
- To report a rare case of seropositive rheumatoid arthritis (RA) developing during adalimumab therapy for ulcerative colitis (UC).
- To review existing literature on the co-occurrence of UC and RA and the impact of TNF inhibitors.
Main Methods:
- Case report of a 70-year-old woman with UC treated with adalimumab.
- Literature review of 30 patients diagnosed with both UC and RA.
Main Results:
- The patient developed seropositive RA while on adalimumab for UC.
- Literature review identified three patients (10%) with RA developing after UC diagnosis.
- This is the first reported case of RA developing during TNF inhibitor therapy for UC.
Conclusions:
- Rheumatoid arthritis can develop in UC patients even when treated with TNF inhibitors.
- This finding underscores the importance of considering RA as a differential diagnosis for arthritis in UC patients, irrespective of anti-TNF treatment.
More Related Videos
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
06:24Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
Published on: October 13, 2023
Related Concept Videos
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...